Human atheromas accumulate extracellular matrix proteins such as collagen types I and III. We tested whether cytokines or growth factors produced by cells found in human atherosclerotic plaques alter collagen gene expression in vascular smooth muscle cells (VSMCs), which produce the blood vessel matrix. Interleukin-l (IL-1, 1-10 ng/ml) modestly increased the synthesis of collagens I and III (measured by tritiated proline incorporation into specific electrophoretic bands), whereas transforming growth factor-^ (TGF-/3) or platelet-derived growth factor (PDGF) markedly stimulated production of these interstitial collagens. Interferon y (IFN-y) 
D evelopment of the complicated arteriosclerotic plaque in humans involves proliferation of vascular smooth muscle cells (VSMCs) and accumulation of extracellular matrix. 1 VSMCs themselves can synthesize various matrix materials, including collagen types I and III, elastin, certain glycosaminoglycans, and microfibrillar proteins. 2 " 5 Therefore, inappropriate production of extracellular matrix constituents by VSMCs likely accounts for excessive formation of the collagenous matrix characteristic of advanced human atheromata and certain other arterial hyperplastic lesions. Knowledge of the regulation of collagen synthesis by these vascular cells would increase understanding of the pathophysiological mechanisms that underlie atherogenesis and might also indicate points in this process susceptible to therapeutic intervention.
Because of the significance of VSMC proliferation and matrix production during morphogenesis of blood vessels and in vascular diseases, many studies have examined the role of serum-associated mitogens, particularly platelet products, in the control of these two smooth muscle functions. Indeed, two major peptide constituents of platelets, platelet-derived growth factor (PDGF) and transforming growth factor-/3 (TGF-/3), can stimulate both division of and collagen protein synthesis by cultured VSMCs. 5 -7 After breeches in endothelial integrity occur (e.g., after balloon angioplasty), release of these two mediators from activated platelets might contribute to the fibrotic response to injury.
Atherogenesis can begin, however, without denudation of the endothelium and without the participation of platelets. 8 Thus, cells other than platelets probably furnish signals that modulate smooth muscle functions early during atheroma formation. Analysis of the cellular composition of complicated human athero-sclerotic plaques has identified prominent infiltration by both mononuclear phagocytes and T lymphocytes in specific spatial distributions. 9 
"
11 These leukocytes constitute an alternative and pathologically relevant source of molecules that might locally regulate functions of vascular wall cells. In particular, monokines such as interleukin-1 (IL-1) stimulate smooth muscle proliferation, at least in part by stimulating endogenous growth factor gene expression.
14 The lymphokine interferon y (IFN-y) limits growth of VSMCs exposed to serum, PDGF, or IL-1. 1516 In fibroblasts grown from human synovia and dermis, IL-1 can augment collagen gene expression.
17
- 19 Furthermore, IFN-y can inhibit collagen production by dermal and synovial fibroblasts in vitro and accumulation of collagenous matrixes in experimentally produced inflammatory lesions in intact animals. 20 - 21 Therefore, we tested whether certain well-characterized mediators likely to be produced by atheroma-associated cells might also modulate collagen gene expression in human VSMCs. Our results establish that cytokines and growth factors do regulate this process in the human cell type important in vascular fibrogenesis and suggest a possible strategy for limiting this process in vivo.
Methods

Cell Preparation and Culture
Smooth muscle cells were cultured by explant outgrowth from unused portions of human saphenous veins from coronary bypass surgery by a protocol approved by the institutional Human Investigation Review Committee. The cell cultures were grown in Dulbecco's modified Eagle's medium (DMEM) (M.A. Bioproducts, Walkersville, Md.) with 10% fetal calf serum (FCS). All tissue culture constituents were selected for low endotoxin levels (<40 pg/ml) by Limulus amoebacyte lysate assay (QCL 1000, M.A. Bioproducts).
Collagen Synthesis
Cells were seeded at 1.5 xlO 5 cells/well in 24-well culture plates and incubated in DMEM with 10% FCS for 3 days, yielding confluent cultures. The medium was then changed, and the cells were incubated with or without the cytokine or growth factor under study. After 2 more days the medium was removed, cells were washed three times with serumfree medium, and 1.0 ml fresh medium without FCS was added that contained /3-aminopropiononitrile (80 fig/ml H]proline, 50 /iCi/ml; Amersham, Arlington Heights, 111.) After an additional 24 hours of culture, a portion of the medium was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (5% acrylamide) under reducing conditions (1% /3-mercaptoethanol) unless otherwise indicated. Twofold-concentrated Laemmli sample solvent that contained /3-mercaptoethanol was added to an equal portion of the sample to be analyzed and was heated to 90°C for 5 minutes before application to the gel. 22 Radioactive bands were visualized by fluorography of the gels. Carbon-14-labeled calf skin collagen (Vitrogen, The Collagen Corporation) was used as a molecular weight marker. Under these conditions the procollagens represent the major [ 3 H]proline-labeled proteins secreted by the cultured VSMCs. In some experiments the labeled collagen in the cell culture medium was further characterized after digestion with pepsin (1 (ig/m\) at 4°C overnight followed by SDS-PAGE (5% acrylamide) with delayed reduction to allow the separation of collagen al(I) from al(III) chains. 23 Results obtained by the use of cells maintained in horse plasma-derived serum (a medium supplement low in PDGF and other coagulation-associated mitogens) were similar to those obtained by study of cells grown in DMEM containing FCS (10%).
RNA Isolation and Northern Analysis
Cells were lysed in 4 M guanidinium isothiocyanate. Total cellular RNA was then isolated by centrifugation through CsCl. 24 RNA was electrophoresed through agarose (1.2%)-formaldehyde (2.2 M) gels, transferred to nylon membranes (Hybond N, Amersham), and fixed by ultraviolet irradiation. Blots were prehybridized for at least 4 hours at 42°C in 50% formamide, 50 mM tris(hydroxymethyl)amino methane/HCl (pH 7.6), 0.75 M NaCl, 0.1% Na 2 H 2 P 2 O 7 ,10 x Denhardt's solution, 10 mM EDTA, 0.1% SDS, and 0.2 mg/ml sheared salmon sperm DNA. Hybridization was performed in the same solution with the addition of dextran sulfate (10%, vol/vol) for 18-24 hours with DNA probes labeled with phosphorus-32-labeled deoxycytidine triphosphate by random hexanucleotide priming to a specific activity greater than 10 8 cpm/ng DNA. Blots were washed at 50°C at a final stringency of 0.1 x standard saline citrate and 0.1% SDS and exposed to Kodak X-Omat AR film at -70°C for up to 5 days. Quantification of autoradiographic bands used an LKB integrating densitometer. The probes used for this study included a 792-bp £coRI to Xho I fragment of HpCl 4.0 a2(I) collagen cDNA, 25 a 701-bp Xho I to EcoKl fragment of RJ5 for al(III) collagen, 2627 and the RBT.3 clone 28 for a constitutive and well-conserved form of /3-tubulin.
Results
IL-1/3 augments collagen synthesis by fibroblasts isolated from human skin or synovia and by chondrocytes. 17 - 19 Similarly, IL-la and /3 produced small but variable effects on collagen biosynthesis in cultured human VSMCs (Figure 1 ). The stimulation of collagen biosynthesis by IL-1 was modest, and in several experiments, negligible. One possible source of such variability is the ability of IL-1 to augment endogenous prostanoid production by human VSMCs. 1217 The cyclooxygenase inhibitor indomethacin (1 /tg/ml) inhibits prostaglandin production from VSMCs induced by IL-1. 12 When this inhibitor was included in parallel incubations, IL-la and /3 still only stimulated collagen biosynthesis slightly (Figure 1 ). In other experiments tumor necrosis factor (TNF-a) and lymphotoxin (also known as TNF-/8) likewise produced small increases in collagen biosynthesis by human VSMCs that were unaffected by coincubation with indomethacin (data not shown).
In contrast, PDGF substantially augmented collagen biosynthesis by cultured human VSMCs in a consistent and dose-dependent manner (Figure 2 , left panel). Of the cytokines and growth factors tested, TGF-/3 produced the greatest increases in collagen synthesis by VSMCs (Figures 2 [left panel] , 3, and 4). Further analysis of the collagens synthesized during metabolic labeling was performed by pepsin digestion of the conditioned medium, followed by PAGE and delayed reduction, which permitted separation of al(I) from al(III) chains. 23 IL-1 had a slight effect on al(I) synthesis but consistently increased al(III) production ( Figure 4) .
The effect of the growth factors and cytokines tested was selective, as overall protein synthesis, estimated by incorporation of sulfur-35-labeled raethionine, did not change under conditions that al-
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tered collagen synthesis (data not shown). Furthermore, the effects of these agents did not appear to depend on alterations in the growth rate of VSMCs, as similar results were obtained with VSMCs that were cultured in serum-free medium supplemented with lactalbumin hydrolysate or in plasma-derived serum, a biologic fluid that lacks substantial mitogenic activity for human VSMCs (data not shown). Likewise, endotoxin contamination of the culture medium did not account for our results. All reagents used were screened for endotoxin by use of the chromogenic Limulus amoebacyte assay that could detect 10 pg/ml of Escherichia coli lipopolysaccharide. Furthermore, experiments in which the endotoxin antagonist polymyxin B was included did not alter the cytokine-and growth factor-mediated effects on collagen synthesis (data not shown).
The cytokine IFN-y decreases collagen synthesis in a variety of experimental situations, both in vitro and in vivo. 1516 There is considerable evidence that human atherosclerotic plaques contain T cells that produce this lymphokine.
30 - 31 We therefore tested whether IFN-y altered. collagen biosynthesis by VSMCs. This lymphokine consistently and profoundly reduced interstitial collagen synthesis by these cells. IFN-y not only decreased the basal synthesis of collagen by VSMCs but also blocked the augmentation in collagen biosynthesis produced by PDGF and TGF-0 (Figures 3 and 4) . This inhibitory effect of IFN-y on collagen synthesis by VSMCs was quite selective, as the lymphokine did not alter incorporation of 35 S-methionine into overall cell proteins (data not shown). IFN-y also selectively alters expression of other genes in VSMCs. For example, this lymphokine specifically induces the expression of major histocompatibility complex class II genes, is > 32 yet reduces expression of a-actin in this cell type. 33 To clarify the mechanism by which these cytokines and growth factors alter collagen metabolism in VSMCs, we measured steady-state mRNA levels by Northern analysis. IL-la and TGF-/3 increased mRNA encoding al(III) and a2(I) procollagens ( Figure 5 ). These treatments did not appreciably alter levels of mRNA for a constitutively expressed form of /3-tubulin. 28 vascular matrix in the development of normal vessels. 34 Dysregulation of matrix production by VSMCs also contributes to the pathogenesis of common vascular diseases. Collagen is a major constituent of human atherosclerotic lesions. Matrix also accumulates in hypertensive arteries, probably due in part to increased collagen synthesis. 35 For these reasons, the capacity of VSMCs to synthesize extracellular matrix constituents has interested investigators since the introduction of modern culture techniques for this cell type. 2336 Burke et al 5 and Burke and Ross 37 found that exposure to platelet products increased collagen synthesis by primate arterial VSMCs. Strepp et al 6 found that collagen production by bovine VSMCs increased with time in culture with serum, even after a plateau in steadystate levels of mRNA encoding type I and type III collagen chains had been reached. Their findings highlight the importance of measuring both mRNA and protein levels to understand the regulation of collagen expression in these cells. More recently, TGF-/3, a product of platelets and monocyte/macrophages as well as vascular endothelial and smooth muscle cells, has emerged as a potent regulator of collagen gene activity in fibroblasts and VSMCs. 7 -38 In the earliest phases of atherogenesis, leukocytes or intrinsic vascular wall cells rather than platelets represent the more likely sources of signals that could alter the functions of vascular cells. We have particularly considered cytokines (protein mediators of immune and inflammatory responses) and growth factors as potentially pathophysiologically relevant regulators of VSMCs. 31 Phagocytic leukocytes, which abound in regions of atheromata, can produce IL-1, TNF, and TGF-/3, substances that alter important functions of both vascular endothelial cells and VSMCs. These two vascular cell types not only respond to IL-1, TNF, and TGF-/3 but also can themselves express the genes that encode these mediators. We report here that IL-1 stimulates expression of the genes for collagen types I and III in human VSMCs, as determined at both the levels of mRNA and protein synthesis. These forms of "interstitial" collagen accumulate in human atheroma. Even maximal concentrations of IL-1 augmented collagen production to a lesser degree than did PDGF or TGF-/3. Because IL-1 may induce VSMC expression of autocrine PDGF-A or heparin-binding growth factor-2 (basic fibroblast growth factor), some or all of IL-l's effect on these cells might be indirect.
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Other cytokine-growth factor interactions reported in mesenchymal cells such as fibroblasts and VSMCs might also pertain to the vessel wall. For example, PDGF stimulates TGF-/3 production 39 and conversely, TGF-/3 induces PDGF production and modulates expression of PDGF receptors. 40 Like IL-1 and PDGF, TGF-/3 can induce its own gene expression. 41 Cultured endothelial cells and VSMCs secrete constitutively the latent form of TGF-/3, as do many cells in vitro. However, coculture of these two vascular cell types, located in proximity in vivo, yields release of active TGF-/3. 4243 These observations illustrate the potential for multilateral cellular interactions in the maintenance of normal homeostasis in the vessel wall and in the pathogenesis of vascular diseases.
Recent immunohistochemical analyses have disclosed that in addition to macrophages, regions of human atheromata contain substantial infiltrates of T lymphocytes.
101144 These T cells bear markers of activation such as surface IL-2 receptors. 30 Activated T cells secrete IFN-% a lymphokine with several recently documented effects on VSMCs. For example, incubation of human VSMCs with IFN-y inhibits PDGF-or IL-1-induced growth, activates 2',5'-oligoadenylate synthetase, and increases class I and induces class II major histocompatibility gene expression.
151632 IFN-y also accentuates the usual "modulated" pattern of actin expression manifested by VSMCs in culture (a predominance of /3-and a-nonmuscle actin) by reducing expression of the a-smooth muscle actin isoform. 33 We report here that IFN-y also profoundly suppresses both basal and stimulated collagen gene expression by VSMCs. Taken together, our observations support the concept that a balance between cytokines or growth factors with opposing effects influences the phenotype of VSMCs within specific regions of the blood vessels. 45 Alterations in the balance of cytokine and growth factor production by intrinsic vascular cells or infiltrating leukocytes in vivo could perturb regional vascular homeostasis and signal alterations in vascular growth and regression during normal growth and development, in tissue repair, and in pathological states. contributes to the regulation of vascular function both in health and in disease.
The observations reported here also have therapeutic implications. For example, an accelerated intimal hyperplastic reaction limits the clinical utility of percutaneous transluminal angioplasty of coronary and peripheral atherosclerosis. 48 About one third of lesions initially successfully dilated will develop restenoses within a matter of months. Accumulation of VSMCs and extracellular matrix characterize these restenotic lesions. Similar hyperplastic lesions contribute to the failure of arteriovenous shunts and vascular bypass grafts, particularly at anastomotic sites. 49 IFN-y simultaneously retards proliferation and reduces collagen synthesis by human VSMCs exposed to a variety of potent cytokines and mitogens thought to participate in vascular pathology.
Indeed, similar observations made with fibroblasts in vitro and in vivo illustrate how the profound inhibition of collagen gene expression induced by IFN-y can benefit disease states characterized by excessive collagen synthesis, for example, progressive sclerosis (scleroderma) or keloids. 50 - 52 Direct instillation of IFN-y into keloids was associated with regression of these lesions. 5051 Injection of IFN-y s0 - 51 or IFN-a 53 into incisional sites after surgical removal of keloids prevented recurrence of the hyperplastic response. These preliminary observations in humans establish that local administration of IFN-y influences collagen synthesis at sites of rapid collagen deposition and can limit fibrotic reactions in vivo. Thus, the present observations illustrate a potential pharmacological approach to simultaneous limitation of both proliferation and collagen synthesis by VSMCs. Brief systemic or short-term localized administration of IFN-y at lesional sites might prove useful in modulating the undesirable intimal proliferative response and matrix accumulation provoked by vascular interventions such as coronary angioplasty.
